Survival analysis of acquired EGFR T790M mutant patients with advanced non⁃small cell lung cancer treated with sequential osimertinib
10.19405/j.cnki.issn1000-1492.2023.07.027
- Author:
Yuenan Wang
1
;
Huanhuan Zhang
2
;
Yuxia Zou
2
;
Xueru Ren
1
;
Hanqi Wang
2
;
Yueyin Pan
3
;
Zhihong Zhang
4
,
5
,
6
Author Information
1. Graduate School , Bengbu Medical College , Bengbu 233030
2. Graduate School , Wannan Medical College , Wuhu 241002
3. Dept of Oncology, The First Afiliated Hospital of USTC , Hefei 230001
4. Graduate School , Bengbu Medical College , Bengbu 233030；Graduate School , Wannan Medical College , Wuhu 241002
5. 3 Dept of Oncology, The First Afiliated Hospital of USTC , Hefei 230001
6. Dept ofPulmonology, The First Afiliated Hospital of USTC West District(Anhui Provincial Hospital West District) , Hefei 230031
- Publication Type:Journal Article
- Keywords:
epidermal growth factor receptor;
EGFR exon 20 T790M mutation;
non⁃small cell lung cancer;
epi⁃ dermal growth factor receptor tyrosine kinase inhibitors;
osimertinib
- From:
Acta Universitatis Medicinalis Anhui
2023;58(7):1222-1227
- CountryChina
- Language:Chinese
-
Abstract:
Objective : To analyze the overall survival( OS) of sequential osimertinib treatment in patients with epidermal growth factor receptor(EGFR) exon 20 T790M mutant advanced non⁃small cell lung cancer(NSCLC) and risk factors of the efficacy of sequential osimertinib treatment.
Methods :The data of 138 advanced NSCLC patients with acquired EGFR exon 20 T790M mutation who took sequential osimertinib as second⁃line treatment. KaplanMeier variable was used for survival analysis. The Log⁃rank method was used for univariate analysis. The COX risk regression model was used for multivariate analysis. The survival status and influencing factors of patients treated with sequential osimertinib were analyzed.
Results : At the last follow⁃up , 99 of the 138 patients died. Median progression free survival (PFS1)of first⁃line of first⁃ or second⁃generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR⁃TKIs) was 11 months (95% CI: 10. 1 - 11. 9) ; median PFS2 of osimertinib was 10 months (95% CI: 8. 5 - 11. 5) ; The median PFS with sequential osimertinib treatment was 24 months(95% CI: 21. 7 -26. 3) , the median OS was 32 months(95% CI: 28. 9 - 35. 1) . In univariate and multivariate analysis , PFS1 was an independent prognostic factor for PFS and OS(P < 0. 001) .
Conclusion :Sequential osimertinib treatment for advanced NSCLC patients with acquired EGFR exon 20 T790M mutation achieved good PFS(24 months) and OS (32 months) .
- Full text:2024102417094273519获得性EGFR_T790M...接受奥希替尼治疗的生存分析_汪岳男.pdf
